Lamotrigin Arrow 50 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lamotrigin arrow 50 mg disperzibilne tablete

arrow generics limited - lamotrigin - disperzibilna tableta - lamotrigin 50 mg / 1 tableta - lamotrigin

Lamotrigin Arrow 100 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lamotrigin arrow 100 mg disperzibilne tablete

arrow generics limited - lamotrigin - disperzibilna tableta - lamotrigin 100 mg / 1 tableta - lamotrigin

Lamotrigin Arrow 5 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lamotrigin arrow 5 mg disperzibilne tablete

arrow generics limited - lamotrigin - disperzibilna tableta - lamotrigin 5 mg / 1 tableta - lamotrigin

Lamotrigin Arrow 50 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lamotrigin arrow 50 mg disperzibilne tablete

arrow generics limited - lamotrigin - disperzibilna tableta - lamotrigin 50 mg / 1 tableta - lamotrigin

Lamotrigin Arrow 200 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lamotrigin arrow 200 mg disperzibilne tablete

arrow generics limited - lamotrigin - disperzibilna tableta - lamotrigin 200 mg / 1 tableta - lamotrigin

Lamotrigin Arrow 25 mg disperzibilne tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lamotrigin arrow 25 mg disperzibilne tablete

arrow generics limited - lamotrigin - disperzibilna tableta - lamotrigin 25 mg / 1 tableta - lamotrigin

Cevenfacta Evropska unija - slovenščina - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - antihemoragije - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.